These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 31961494)

  • 1. Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
    Bingham CO; Bartlett SJ; Kannowski C; Sun L; DeLozier AM; Cella D
    Arthritis Care Res (Hoboken); 2021 Apr; 73(4):481-488. PubMed ID: 31961494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
    Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
    Smolen JS; Kremer JM; Gaich CL; DeLozier AM; Schlichting DE; Xie L; Stoykov I; Rooney T; Bird P; Sánchez Bursón JM; Genovese MC; Combe B
    Ann Rheum Dis; 2017 Apr; 76(4):694-700. PubMed ID: 27799159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.
    Li ZG; Hu JK; Li XP; Yang Y; Li XF; Xu JH; Zhang X; Xu J; Bao CD; He DY; Li ZJ; Wang GC; Zuo XX; Liu Y; Xiao ZY; Chen JW; Xin XF; Li JY; Jiang LD; Liu MR; Ji F; Li CG
    Adv Ther; 2021 Jan; 38(1):772-781. PubMed ID: 33237533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.
    Bingham CO; Gaich CL; DeLozier AM; Engstrom KD; Naegeli AN; de Bono S; Banerjee P; Taylor PC
    Trials; 2019 Mar; 20(1):182. PubMed ID: 30902094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
    Tanaka Y; Atsumi T; Amano K; Harigai M; Ishii T; Kawaguchi O; Rooney TP; Akashi N; Takeuchi T
    Mod Rheumatol; 2018 Jul; 28(4):583-591. PubMed ID: 29134891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Baricitinib 4 mg for the Treatment of Moderate to Severe Rheumatoid Arthritis.
    Dabal TD; Haltom MB; Patel PP; Son CK; Joglekar KP; Groeschell CM; Chumpia MM; Kamal SF; Seth A; Jackson CD
    South Med J; 2021 May; 114(5):288-292. PubMed ID: 33942113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
    Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
    J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study.
    Caporali R; Taylor PC; Aletaha D; Sanmartí R; Takeuchi T; Mo D; Haladyj E; Bello N; Zaremba-Pechmann L; Fang Y; Dougados M
    Rheumatology (Oxford); 2024 Oct; 63(10):2799-2809. PubMed ID: 38258434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study.
    Smolen JS; Xie L; Jia B; Taylor PC; Burmester G; Tanaka Y; Elias A; Cardoso A; Ortmann R; Walls C; Dougados M
    Rheumatology (Oxford); 2021 May; 60(5):2256-2266. PubMed ID: 33200220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K
    Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rare case of symptomatic creatine kinase elevation in a patient with rheumatoid arthritis treated with baricitinib.
    Mariani FM; Alunno A; Carubbi F; Ferri C
    Reumatismo; 2024 Jun; 76(2):. PubMed ID: 38916168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Janus kinase inhibitor baricitinib for rheumatoid arthritis : Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM)].
    Alten R; Nitschmann S
    Internist (Berl); 2017 Dec; 58(12):1341-1344. PubMed ID: 29119202
    [No Abstract]   [Full Text] [Related]  

  • 17. PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs.
    van de Laar CJ; Oude Voshaar MAH; Ten Klooster P; Tedjo DI; Bos R; Jansen T; Willemze A; Versteeg GA; Goekoop-Ruiterman YPM; Kroot EJ; van de Laar M
    RMD Open; 2024 May; 10(2):. PubMed ID: 38816210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
    Smolen JS; Genovese MC; Takeuchi T; Hyslop DL; Macias WL; Rooney T; Chen L; Dickson CL; Riddle Camp J; Cardillo TE; Ishii T; Winthrop KL
    J Rheumatol; 2019 Jan; 46(1):7-18. PubMed ID: 30219772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis.
    Saito K; Yoshida S; Ebina H; Miyata M; Suzuki E; Kanno T; Sumichika Y; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    PLoS One; 2024; 19(7):e0306714. PubMed ID: 38990897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.